




The relative strengths and weaknesses of Insys Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Insys Therapeutics Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Insys Therapeutics Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 370%, being 116% points above the market average of 254%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	151,042	Assets	215,121
Cost of Goods Sold	22,578	Liabilities	49,454
Intangible Assets	0	Expenses	184,301
Liabilities, Current	45,676	Revenues	222,125
Liabilities, Non-Current	0	Stockholders Equity	165,667
Other Assets	34,207	Net Income	37,977
Other Compr. Net Income	-24	Comprehensive Net Income	37,965
Other Expenses	84,304	BaseVar	335,589
Other Liabilities	3,778	ECR before LimitedLiability	302%
Other Net Income	153	Economic Capital Ratio	370%
Other Revenues	222,125		
Property and Equipment	29,872		
Research and Development	33,136		
Selling, General and Administrative Expense	44,283		